Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Strategies to enhance CAR-T persistence
Yue Liu, Lingna An, Ruihao Huang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 57
Harnessing the potential of hydrogels for advanced therapeutic applications: current achievements and future directions
Peilin Lu, Dongxue Ruan, Meiqi Huang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 42
Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology
Ruiyu Tao, Xiaopeng Han, Xue Bai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 19
CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
Wei Wei, Zhi‐Nan Chen, Ke Wang
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12317-12317
Open Access | Times Cited: 30
New cell sources for CAR-based immunotherapy
Marzieh Mazinani, Fatemeh Rahbarizadeh
Biomarker Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 24
CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)
Dahua Sun, Xiang Shi, Sanyan Li, et al.
Molecular Medicine Reports (2024) Vol. 29, Iss. 3
Open Access | Times Cited: 9
Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments
Yan Zhuo, Zhengbo Zhang, Yanan Chen, et al.
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Praneeth Reddy Keesari, Diana Samuels, Charan Thej Reddy Vegivinti, et al.
Current Hematologic Malignancy Reports (2025) Vol. 20, Iss. 1
Open Access
Exploring CAR-macrophages in non-tumor diseases: Therapeutic potential beyond cancer
Yizhao Chen, Qianling Xin, Mengjuan Zhu, et al.
Journal of Advanced Research (2025)
Open Access
Charged substrate treatment enhances T cell mediated cancer immunotherapy
Jia Song, Yanhui Lu, Lulu Liu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
The role of MSCs and CAR-MSCs in cellular immunotherapy
Lun Yan, Jing Li, Cheng Zhang
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 18
Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes
Priyanka Maridhi Nanjireddy, Scott H. Olejniczak, Nataliya P. Buxbaum
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Unlocking the potential of T‐cell metabolism reprogramming: Advancing single‐cell approaches for precision immunotherapy in tumour immunity
Lihaoyun Huang, Haitao Li, Cangang Zhang, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 5
A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives
Megan Montoya, Marco Gallus, Su Phyu, et al.
Cells (2024) Vol. 13, Iss. 9, pp. 726-726
Open Access | Times Cited: 5
CAR-macrophage: Breaking new ground in cellular immunotherapy
Ting Huang, Chenqi Bei, Zhenhua Hu, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 4
Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
Maria V. Alvanou, Memnon Lysandrou, Panayota Christophi, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1935-1935
Open Access | Times Cited: 13
Immunotherapy for colorectal cancer
Bing Yu, Jian Kang, Hong Lei, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment
Qinghui Xiong, Haiying Wang, Qiushuang Shen, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
CAR-Based Therapy for Autoimmune Diseases: A Novel Powerful Option
Györgyi Műzes, Ferenc Sípos
Cells (2023) Vol. 12, Iss. 11, pp. 1534-1534
Open Access | Times Cited: 8
Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy
Shan-Shan Zhen, Wenqian Wang, Guohui Qin, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Current strategies to improve CAR-T cell persistence
Soren K Ghorai, Ashley N. Pearson
(2024)
Open Access | Times Cited: 2
Current Strategies to Improve Chimeric Antigen Receptor T (CAR-T) Cell Persistence
Soren K Ghorai, Ashley N. Pearson
Cureus (2024)
Open Access | Times Cited: 2
Current status and future challenges of CAR-T cell therapy for osteosarcoma
Shizhe Li, He Zhang, Guanning Shang
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Ginsenoside Rg1 improves anti-tumor efficacy of adoptive cell therapy by enhancing T cell effector functions
Yue Liu, Lingna An, Chengfei Yang, et al.
Blood Science (2023)
Open Access | Times Cited: 6
Mechanism of action and treatment of type I interferon in hepatocellular carcinoma
Chunxiu Peng, Zhijian Ye, Ying Ju, et al.
Clinical & Translational Oncology (2023) Vol. 26, Iss. 2, pp. 326-337
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top